FATE
HEALTHCAREFate Therapeutics Inc
$2.29-0.07 (-2.97%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving FATE Today?
No stock-specific AI insight has been generated for FATE yet. However, FATE was mentioned in the following AI insights:
52-Week Range
$0.91$2.47
$2.29
Fundamentals
Market Cap$266M
P/E Ratio—
EPS$-1.15
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume5.9M
Avg Volume (10D)—
Shares Outstanding116.3M
FATE News
22 articles- Fate Therapeutics (FATE) officer exercises 166,664 options, holds 609k sharesStock Titan·May 8, 2026
- CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 7, 2026
- Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseYahoo Finance·May 6, 2026
- Novavax (NVAX) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819Yahoo Finance·May 5, 2026
- Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune DiseasesYahoo Finance·May 4, 2026
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 1, 2026
- Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 MeetingYahoo Finance·Apr 30, 2026
- Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual MeetingYahoo Finance·Apr 16, 2026
- Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham ConferenceMarketbeat·Apr 16, 2026
- Fate Therapeutics to Participate in Upcoming Second Quarter 2026 ConferencesYahoo Finance·Apr 9, 2026
- Scalable Biotech Manufacturing Unlocks a $14B MarketBenzinga·Mar 27, 2026
- Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at ConferenceMarketbeat·Mar 16, 2026
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 4, 2026
- Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare ConferenceYahoo Finance·Mar 3, 2026
- Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Feb 26, 2026
- Fate Therapeutics: Q4 Earnings SnapshotYahoo Finance·Feb 26, 2026
- Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdatesYahoo Finance·Feb 26, 2026
- Companies Like Fate Therapeutics (NASDAQ:FATE) Could Be Quite RiskyYahoo Finance·Dec 21, 2025
- Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell ProgramsYahoo Finance·Dec 8, 2025
- Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare ConferenceYahoo Finance·Nov 25, 2025
- Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue EstimatesYahoo Finance·Nov 13, 2025
All 22 articles loaded
Price Data
Open$2.40
Previous Close$2.36
Day High$2.41
Day Low$2.16
52 Week High$2.47
52 Week Low$0.91
52-Week Range
$0.91$2.47
$2.29
Fundamentals
Market Cap$266M
P/E Ratio—
EPS$-1.15
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume5.9M
Avg Volume (10D)—
Shares Outstanding116.3M
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—